U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Safety-related Labeling Changes

Drug Safety-related Labeling Changes (SrLC)

Get Email Alerts | Guide

KYBELLA (NDA-206333)

(DEOXYCHOLIC ACID)

Safety-related Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)

Download Data

Expand all

09/11/2026 (SUPPL-6)

Approved Drug Label (PDF)

6 Adverse Reactions

6.2 Postmarketing Experience

Additions and/or revisions underlined:

The following adverse reactions have been identified during post-approval use of KYBELLA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA exposure.

        • Administration Site Conditions: injection site ulceration, necrosis, mass, infection, alopecia, and scarring.

 

…

09/11/2026 (SUPPL-7)

Approved Drug Label (PDF)

4 Contraindications

Additions and/or revisions underlined:

KYBELLA is contraindicated in patients with an infection in the injection area.

5 Warnings and Precautions

5.1 Marginal Mandibular Nerve Injury

Additions and/or revisions underlined:

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported in KYBELLA-treated patients during clinical trials. All marginal mandibular nerve injuries reported from the trials resolved without additional treatment (range 1-298 days, median 44 days). To avoid the potential for marginal mandibular nerve injury, do not inject KYBELLA into or in close proximity to the marginal mandibular branch of the facial nerve [see Dosage and Administration (2.3)].

5.2 Dysphagia

Additions and/or revisions underlined:

Difficulty swallowing (dysphagia) occurred in KYBELLA-treated patients in clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Cases of dysphagia resolved without additional treatment (range 1-81 days, median 3 days).

Subjects with current or prior history of dysphagia were excluded from clinical trials.

Avoid use of KYBELLA in patients with a current or prior history of dysphagia because KYBELLA use may exacerbate the condition.

5.3 Injection Site Reactions

Subsection title revised

Additions and/or revisions underlined:

Injection Site Hematoma or Bruising

In clinical trials, 72% of subjects treated with KYBELLA had an injection site hematoma or bruising [see Adverse Reactions (6.1)].

Use KYBELLA with caution in patients with bleeding abnormalities (e.g., taking antiplatelet or anticoagulant therapy) as excessive bleeding or bruising in the treatment area may occur.

Injection Site Alopecia

Cases of injection site alopecia have been reported with KYBELLA administration. The onset and duration of this adverse reaction may vary among individuals and may persist.

Consider withholding subsequent KYBELLA treatments until resolution of this adverse reaction.

Injection Site Ulceration, Necrosis, Nodule, Mass, and Infection

Very superficial injections (into the dermis) of KYBELLA may result in skin ulceration and necrosis [see Dosage and Administration (2.3)]. Cases of injection site ulceration, necrosis, nodule (less than or equal to 3 cm in diameter), mass (> 3 cm in diameter), and infection have been reported with KYBELLA administration. Nodules or masses may occur following initial or subsequent KYBELLA administration. Some nodules and masses may not resolve and medical intervention may be required. Some cases of injection site infection have included cellulitis and abscess requiring intravenous antibiotic treatment and incision and drainage.

Discontinue KYBELLA if patients develop injection site ulceration, necrosis, nodule, mass, or infection after KYBELLA administration.

5.4 Risk of Injecting in Proximity to Vulnerable Anatomic Structures

Newly added subsection:

To avoid potential tissue damage, do not inject KYBELLA into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.

Avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury.

5.5 Serious Adverse Reactions Associated with Unapproved Use Outside the Submental Region

Newly added subsection:

Serious adverse reactions have been reported following unapproved administration of KYBELLA outside the submental region (e.g., blurred or reduced vision with periorbital use, muscle or nerve injury including facial paresis and paresthesia). Cases of injection site nodules (less than or equal to 3 cm in diameter) and masses (> 3 cm in diameter) have also been reported following initial or subsequent administration of KYBELLA outside the submental region. The nodules and masses may not resolve and medical intervention may be required.

KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region [see Indications and Usage (1)].

6 Adverse Reactions

6.1 Clinical Trials Experience

Additions and/or revisions underlined:

…

Adverse reactions that lasted more than 30 days and occurred in more than 10% of KYBELLA-treated subjects were injection site numbness (42%), injection site edema/swelling (20%), injection site pain (16%), and injection site induration (13%).

8 Use in Specific Populations

8.4 Pediatric Use

Additions and/or revisions underlined:

Safety and effectiveness of KYBELLA have not been established in pediatric patients and KYBELLA is not recommended for use in children or adolescents.

8.5 Geriatric Use

Additions and/or revisions underlined:

The clinical trials of KYBELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger adult subjects.

17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)

PATIENT COUNSELING INFORMATION

Additions and/or revisions underlined:

…

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Advise patients to contact their healthcare providers if they develop signs of marginal mandibular nerve paresis (e.g., asymmetric smile, facial muscle weakness) or difficulty swallowing, or if existing symptoms worsen [see Warnings and Precautions (5.1, 5.2)].

Advise patients to contact their healthcare providers if they develop injection site hematoma, brusing, alopecia, ulceration, necrosis, nodule, mass, infection, pain, numbness, induration, or paresthesia from the treatment area [see Warnings and Precautions (5.3)].

PATIENT INFORMATION

Additions and/or revisions underlined:

KYBELLA® (kye be lah) (deoxycholic acid) injection for subcutaneous use

What is KYBELLA?

KYBELLA is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called “double chin.”

The use of KYBELLA for the treatment of fat outside of the submental area is not recommended.

It is not known if KYBELLA is safe and effective in children under 18 years of age.

…

What are the possible side effects of KYBELLA?
…

  • Injection site problems including:

…

    • nodules (less than or equal to 3 cm in diameter) or mass (> 3 cm in diameter). Some nodules and masses may not resolve, and medical treatment, may be required.

    • Infection

  • KYBELLA can cause serious side effects when injected into areas of the body other than below the chin (submental area) including:

    • blurred or reduced vision when injected around the eyes

    • muscle or nerve damage, including numbness and tingling in the face

    • lumps or nodules where the injection was given. These lumps or nodules may not resolve in time and medical treatment, may be required

…

10/05/2022 (SUPPL-5)

Approved Drug Label (PDF)

5 Warnings and Precautions

5.6 Injection site ulceration, necrosis, and infection

Additions and/or revisions underlined:

Injections that are too superficial (into the dermis) may result in skin ulceration and necrosis [see Injection Technique (2.3)]. Cases of injection site ulceration, necrosis, and infection have been reported with the administration of KYBELLA. Some cases of injection site infection have included cellulitis and abscess requiring intravenous antibiotic treatment and incision and drainage. Do not administer KYBELLA into the affected area until complete resolution of the adverse reaction.

6 Adverse Reactions

6.2 Postmarketing Experience

Additions and/or revisions underlined:

The following adverse reactions have been identified during post-approval use of KYBELLA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA exposure.

Administration site conditions: injection site ulceration, necrosis, infection, alopecia, and scarring.

17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)

17 PATIENT COUNSELING INFORMATION

Additions and/or revisions underlined:

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Advise patients to contact their healthcare providers if patients begin to develop signs of marginal mandibular nerve paresis (e.g., asymmetric smile, facial muscle weakness), difficulty swallowing, or worsening of existing symptoms.

Advise patients to contact their healthcare providers for development of erythema, pain, open sore(s) or drainage from the treatment area.

05/20/2020 (SUPPL-2)

Approved Drug Label (PDF)

6 Adverse Reactions

6.2 Postmarketing Experience

(Additions and/or revisions underlined)

The following adverse reactions have been identified during post-approval use of KYBELLA®. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA® exposure.

Administration site conditions: injection site ulceration, necrosis, alopecia, and scarring.

Immune System Disorders: Hypersensitivity reactions including rash, urticaria, and itching.

Nervous System Disorders: Oral hypoaesthesia and oral paraesthesia.

8 Use in Specific Populations

8.5 Geriatric Use

(Additions and/or revisions underlined)

The clinical trials of KYBELLA® did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)

PATIENT INFORMATION

(Additions and/or revisions underlined)

…

Call your healthcare provider if you:

  • begin to develop weakness in the muscles of your face, or your smile becomes uneven

  • you have difficulty swallowing, or if any of the symptoms that you already have get worse

  • develop open sores or drainage from the treatment area

The most common side effects of KYBELLA include:

  • swelling               redness

  • pain                     areas of hardness in the treatment area

  • numbness

These are not all of the possible side effects of KYBELLA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

…

05/20/2020 (SUPPL-3)

Approved Drug Label (PDF)

5 Warnings and Precautions

5.4 Risk of injecting in proximity to vulnerable anatomic structures

(Additions and/or revisions underlined)

To avoid potential tissue damage, KYBELLA® should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.

Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury.

6 Adverse Reactions

6.2 Postmarketing Experience

(Additions and/or revisions underlined)

The following adverse reactions have been identified during post-approval use of KYBELLA®. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA® exposure.

Administration site conditions: injection site ulceration, necrosis, alopecia, and scarring.

Immune System Disorders: Hypersensitivity reactions including rash, urticaria, and itching.

Nervous System Disorders: Oral hypoaesthesia and oral paraesthesia.

Procedural Complications: Vascular injury due to inadvertent intravascular injection.

8 Use in Specific Populations

8.5 Geriatric Use

(Additions and/or revisions underlined)

The clinical trials of KYBELLA® did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)

PATIENT INFORMATION

(Additions and/or revisions underlined)

…

What are the possible side effects of KYBELLA? KYBELLA can cause serious side effects, including:

  • Nerve injury in the jaw that can cause an uneven smile or facial muscle weakness

  • Trouble swallowing

  • Injection site problems including:

    • a collection of blood under the skin (hematoma) or bruising

    • damage to an artery or vein if KYBELLA is inadvertently injected into it

    • hair loss

    • open sores (ulcers)

    • damage and tissue cell-death (necrosis) around the injection site

...

01/18/2018 (SUPPL-1)

Approved Drug Label (PDF)

4 Contraindications

(Additions and/or revisions are underlined)

KYBELLA® (deoxycholic acid) injection is contraindicated in the presence of infection at the injection sites.

5 Warnings and Precautions

5.1 Marginal mandibular nerve injury

(Additions and/or revisions are underlined)

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported during clinical trials. To avoid the potential for nerve injury, KYBELLA® (deoxycholic acid) injection should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve…

5.5 Injection site alopecia

(Newly added subsection)

Cases of injection site alopecia have been reported with the administration of KYBELLA®. The onset and duration of this adverse reaction may vary among individuals and may persist. Consider withholding subsequent treatments until resolution of the adverse reaction.

5.6 Injection site ulceration and necrosis

(Newly added subsection)

Injections that are too superficial (into the dermis) may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with the administration of KYBELLA®. Do not administer KYBELLA® into the affected area until complete resolution of the adverse reaction.

6 Adverse Reactions

6.1 Clinical Trials Experience

(Additions and/or revisions are underlined)

In two double-blind, placebo-controlled clinical trials 513 subjects were treated with KYBELLA® (deoxycholic acid) injection and 506 subjects were treated with placebo…

6.2 Postmarketing Experience

(Newly added subsection)

The following adverse reactions have been identified during post-approval use of KYBELLA®. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA® exposure.

Administration site conditions: injection site ulceration, necrosis and alopecia.

8 Use in Specific Populations

8.1 Pregnancy

(Additions and/or revisions are underlined)

Risk Summary

There are no adequate and well-controlled studies of KYBELLA® (deoxycholic acid) injection in pregnant women to inform the drug-associated risk…

17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)

17 PATIENT COUNSELING INFORMATION

(Additions and/or revisions are underlined)

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Advise patients to contact their healthcare providers if patients begin to develop signs of marginal mandibular nerve paresis (e.g., asymmetric smile, facial muscle weakness), difficulty swallowing, or worsening of existing symptoms.

Advise patients to contact their healthcare providers for development of open sores(s) or drainage from the treatment area.